PDCD1 and non-small cell lung carcinoma: PD-L1 expression levels have been demonstrated to be positively correlated with clinical benefits for patients with NSCLC receiving PD-1 inhibitor therapy (Wu and Lu, 2020; Powell et al., 2021).